Napo Pharmaceuticals to Present New Crofelemer (Mytesi) Data at International Aids Society Conference on HIV Science
Presentation will cover new data on the long-term efficacy of crofelemer (Mytesi®) based on a supplemental analysis of the ADVENT trial
Presentation Title: Long-Term Crofelemer Use Gives Clinically Relevant Reductions in HIV-Related Diarrhea
Date and Time of Presentation:
Dates and Time of Poster Display:
Location: Poster Exhibition area
Abstract Number: A-854-0101-01472
The poster for Napo’s presentation will be available on the IAS website in July after the conference begins.
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the
For more information, please visit www.napopharma.com.
For more information about Jaguar, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding the proposed merger
between Jaguar and Napo, the expectation that the proposed merger will
close by the end of